Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia

References

• Sperka T, Wang J, Rudolph KL. DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol. 2012;13(9):579–590.
   PubMed Web of Science ®Google Scholar
• Ouillette P, Li J, Shaknovich R, et al. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2012;51(12):1125–1132.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.
   PubMed Web of Science ®Google Scholar
• Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007;25(34):5448–5457.
   PubMed Web of Science ®Google Scholar
• Stankovic T, Skowronska A. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55(6):1227–1239.
   PubMed Web of Science ®Google Scholar
• Marasca R, Maffei R, Martinelli S, et al. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Hematol Oncol. 2013;31(2):88–95.
   PubMed Web of Science ®Google Scholar
• Guarini A, Marinelli M, Tavolaro S, et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica. 2012;97(1):47–55.
   PubMed Web of Science ®Google Scholar
• Skowronska A, Parker A, Ahmed G, et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom leukemia research fund chronic lymphocytic leukemia 4 trial. J Clin Oncol. 2012;30(36):4524–4532.
   PubMed Web of Science ®Google Scholar
• Hu Z, Medeiros LJ, Fang L, et al. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. Am J Hematol. 2017;92(5):441–447.
   PubMed Web of Science ®Google Scholar
• Jain P, Aoki E, Keating M, et al. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol. 2017;28(7):1554–1559.
   PubMed Web of Science ®Google Scholar
• Kiel MJ, Velusamy T, Rolland D, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014;124(9):1460–1472.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Schaffner C, Litterst A, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med. 1997;3(10):1155–1159.
   PubMed Web of Science ®Google Scholar
• Taylor AM, Metcalfe JA, Thick J, et al. Leukemia and lymphoma in ataxia telangiectasia. Blood. 1996;87(2):423–438.
   PubMed Web of Science ®Google Scholar
• Cuneo A, Bigoni R, Rigolin GM, et al. Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin’s lymphoma: correlation with clinicobiologic features. J Clin Oncol. 2000;18(13):2607–2614.
   PubMed Web of Science ®Google Scholar
• Schaffner C, Idler I, Stilgenbauer S, et al. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA. 2000;97(6):2773–2778.
   PubMed Web of Science ®Google Scholar
• Boultwood J. Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J Clin Pathol. 2001;54(7):512–516.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Byrd JC, Abramson JS, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(2):185–217.
   PubMed Web of Science ®Google Scholar
• Chun K, Wenger GD, Chaubey A, et al. Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: an evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. Cancer Genet. 2018;228–229:236–250.
   PubMed Web of Science ®Google Scholar
• Kanagal-Shamanna R, Jain P, Patel KP, et al. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019;125(4):559–574.
   PubMed Web of Science ®Google Scholar
• Hu B, Patel KP, Chen HC, et al. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol. 2019;185(5):852–864.
   PubMed Web of Science ®Google Scholar
• Blackburn PR, Smadbeck JB, Znoyko I, et al. Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia. Genes Chromosomes Cancer. 2020;59(7):422–427.
   PubMed Web of Science ®Google Scholar
• Peterson JF, Baughn LB, Ketterling RP, et al. Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies. Blood Adv. 2019;3(8):1298–1302.
   PubMed Web of Science ®Google Scholar
• Rowsey RA, Smoley SA, Williamson CM, et al. Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion. Blood Cancer J. 2019;9(10):81.
   PubMedGoogle Scholar
• Schultz MJ, Blackburn PR, Cogbill CH, et al. Characterization of a cryptic PML-RARA fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative RARA FISH studies. Leuk Lymphoma. 2020;61(4):975–978.
   PubMed Web of Science ®Google Scholar
• Smadbeck J, Peterson JF, Pearce KE, et al. Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. Blood Cancer J. 2019;9(12):103.
   PubMedGoogle Scholar
• Tan YQ, Tan YQ, Cheng DH. Whole-genome mate-pair sequencing of apparently balanced chromosome rearrangements reveals complex structural variations: two case studies. Mol Cytogenet. 2020;13:15.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Challagundla P, Jorgensen JL, Kanagal-Shamanna R, et al. Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms. Arch Pathol Lab Med. 2014;138(7):903–909.
   PubMed Web of Science ®Google Scholar
• Admirand JH, Knoblock RJ, Coombes KR, et al. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol. 2010;23(11):1518–1523.
   PubMed Web of Science ®Google Scholar
• Miller RM, Nworu C, McKee L, et al. Development of an immunohistochemical assay to detect the Ataxia-Telangiectasia mutated (ATM) protein in gastric carcinoma. Appl Immunohistochem Mol Morphol. 2020;28(4):303–310.
   PubMedGoogle Scholar
• McGowan-Jordan J, Simons A, Schmid M. ISCN 2016: an international system for human cytogenomic nomenclature. Vol. 149. Basel: Karger; 2016.
   Google Scholar
• Johnson SH, Smadbeck JB, Smoley SA, et al. SVAtools for junction detection of genome-wide chromosomal rearrangements by mate-pair sequencing (MPseq). Cancer Genet. 2018;221:1–18.
   PubMed Web of Science ®Google Scholar
• Smadbeck JB, Johnson SH, Smoley SA, et al. Copy number variant analysis using genome-wide mate-pair sequencing. Genes Chromosomes Cancer. 2018;57(9):459–470.
   PubMed Web of Science ®Google Scholar
• Khanna KK, Lavin MF, Jackson SP, et al. ATM, a Central controller of cellular responses to DNA damage. Cell Death Differ. 2001;8(11):1052–1065.
   PubMed Web of Science ®Google Scholar
• Choi M, Kipps T, Kurzrock R. ATM mutations in cancer: therapeutic implications. Mol Cancer Ther. 2016;15(8):1781–1791.
   PubMed Web of Science ®Google Scholar
• Peterson JF, Pitel BA, Smoley SA, et al. Detection of a cryptic NUP214/ABL1 gene fusion by mate-pair sequencing (MPseq) in a newly diagnosed case of pediatric T-lymphoblastic leukemia. Cold Spring Harb Mol Case Stud. 2019;5(2):a003533.
   PubMed Web of Science ®Google Scholar
• Schulein-Volk C, Wolf E, Zhu J, et al. Dual regulation of Fbw7 function and oncogenic transformation by Usp28. Cell Rep. 2014;9(3):1099–1109.
   PubMed Web of Science ®Google Scholar
• Fong CS, Mazo G, Das T, et al. 53BP1 and USP28 mediate p53-dependent cell cycle arrest in response to centrosome loss and prolonged mitosis. Elife. 2016;5:e16270.
   PubMed Web of Science ®Google Scholar
• Richter K, Paakkola T, Mennerich D, et al. USP28 deficiency promotes breast and liver carcinogenesis as well as tumor angiogenesis in a HIF-independent manner. Mol Cancer Res. 2018;16(6):1000–1012.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu Z, Zhang L, et al. Targeting deubiquitinase USP28 for cancer therapy. Cell Death Dis. 2018;9(2):186.
   PubMedGoogle Scholar
• Gardiner A, Parker H, Glide S, et al. A new minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia. Leuk Res. 2012;36(3):307–310.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen HC, Su X, et al. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2). Blood Cancer J. 2016;6(9):e465.
   PubMed Web of Science ®Google Scholar
• Mikeska T, Carney DA, Seymour JF, et al. No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(7):1420–1422.
   PubMed Web of Science ®Google Scholar